The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology firm headquartered at the Cambridge Biomedical Campus in Cambridge, UK. The company boasts a diverse portfolio of products aimed at treating major diseases in areas such as oncology, cardiovascular health, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation.
Founded in 1999 through the merger of Swedish Astra AB and British Zeneca Group, it includes offerings for both primary and specialty care, coverage for rare diseases, and maintains a strong global presence across various regions. Since the merger, AstraZeneca has consistently ranked among the largest pharmaceutical companies worldwide and has executed numerous corporate acquisitions, such as Cambridge Antibody Technology, MedImmune, Spirogen, and Definiens. Its research and development efforts are concentrated in three strategic centers: Cambridge in the UK, Gothenburg in Sweden, and Gaithersburg in Maryland, US.
AstraZeneca’s corporate lineage can be traced back to 1913, when Astra AB was established by a significant group of physicians and pharmacists in Södertälje. Throughout the 20th century, Astra AB evolved into Sweden's largest pharmaceutical company. Its British counterpart, Zeneca PLC, was created in 1993 when ICI divested its pharmaceuticals division; six years later, Astra AB and Zeneca PLC merged, designating the United Kingdom as the headquarters.
AstraZeneca's primary listing is on the London Stock Exchange, where it is part of the FTSE 100 Index, alongside a secondary listing on Nasdaq Stockholm. It is also traded on the American Nasdaq and is included in the Nasdaq-100 index. AstraZeneca ranks among the pharmaceutical companies globally with one of the highest market capitalizations.
The company's current financial score is 9.00, which is higher than the Pharmaceuticals industry's average of 7.77. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 14.46B, representing a year-over-year increase of 11.74%, while its net profit experienced a year-over-year increase of 27.14%.
Key Metrics
The company’s current valuation score is 8.13, which is higher than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is 31.14, which is 251.58% below the recent high of 109.47 and 17.49% above the recent low of 25.69.
The company’s current earnings forecast score is 8.46, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for AstraZeneca PLC is 93.34, with a high of 232.41 and a low of 67.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The company’s current price momentum score is 9.26, which is higher than the Pharmaceuticals industry's average of 7.02. Sideways: Currently, the stock price is trading between the resistance level at 88.68 and the support level at 75.79, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.59. The latest institutional shareholding proportion is 16.69%, representing a quarter-over-quarter decrease of 2.37%. The largest institutional shareholder is PRIMECAP Management, holding a total of 41.20M shares, representing 1.33% of shares outstanding, with 0.43% increase in holdings.
The company’s current risk assessment score is 9.28, which is higher than the Pharmaceuticals industry's average of 5.11. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
